Now FDA-cleared for
MRD testing of bone
marrow from myeloma &
B-ALL patients
by immunosequencing
Adaptive Biotechnologies is a pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.
The accuracy and sensitivity of our immunosequencing platform drives groundbreaking research in cancer and other immune-mediated diseases. We are also committed to translating immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.
The Power of Immunosequencing
Learn how sequencing T- and B-cell receptors is being used to advance scientific discovery.
clonoSEQ & MRD
Learn about clonoSEQ and how it identifies and tracks measurable residual disease (MRD).
in the news
features
The First & Only FDA-Cleared MRD Assay in Any Lymphoid Cancer
clonoSEQ is now FDA-cleared to detect and monitor MRD in bone marrow from multiple myeloma and B-cell ALL patients
ADAPTIVE'S TERMS OF USE AND PRIVACY POLICIES APPLY TO THE USE OF THIS SITE
The Terms of Use and Online Privacy Policy govern the use of this web site and other online resources Adaptive provides that link to those documents. The Privacy Shield Policy describes the commitments Adaptive has made to protect personal data it receives from third parties located in the European Union or Switzerland. The HIPAA policy is Adaptive’s Notice of Privacy Practices for patients whose personal health information is received or created by Adaptive for diagnostic and related purposes. Adaptive may update, change, add, or delete policies in its sole discretion without notice to you. You have an affirmative obligation to review the web site from time to time and read and understand the policies. To the fullest extent permitted by applicable law, by using this web site, you expressly agree to this.